Bedrijfsoverzicht
Fortress Biotech, Inc. is a biopharmaceutical enterprise dedicated to the development and commercialization of specialized biopharmaceutical products, with a specific focus on the dermatology sector. The company operates within the Healthcare sector and the Biotechnology industry, a classification that positions it as a non-essential consumer discretionary entity where value is derived from intellectual property, clinical trial success, and regulatory approval rather than traditional manufacturing scale. As of the latest reporting period, the company maintains a market capitalization of $75.68M and reports an annual revenue of $63.26M while employing a workforce of 78 individuals. These financial dimensions indicate that Fortress Biotech functions as a small-cap entity with a relatively modest revenue base, suggesting a business model that relies heavily on high-growth potential and efficient capital allocation rather than established market dominance or large-scale operations typical of major pharmaceutical corporations.
Financiële gezondheid
The company reported a revenue of $63.26M over the trailing twelve months, yet it simultaneously recorded a net income of $-1,882,000 and an EBITDA of $-65,560,000. The substantial gap between the positive revenue figure and the negative net income reveals a cost structure characterized by significant operating expenses that are not fully offset by gross profit, a common characteristic in early-stage biotechnology firms where research and development costs are high. Furthermore, the free cash flow stands at $-47,286,376, which indicates that the company is consuming cash reserves to fund its operations and strategic initiatives rather than generating surplus liquidity from its current business activities. Analyzing the three key margins provides deeper insight into this financial reality: the gross margin is 48.1%, suggesting that the cost of goods sold consumes less than half of revenue; however, the operating margin is -29.8% and the profit margin is 10.8%, highlighting that overhead costs and other expenses are eroding profitability to a point where the company operates at a loss despite positive sales figures. In terms of balance sheet strength, Fortress Biotech holds $79.38M in cash against $67.22M in debt, resulting in a debt-to-equity ratio of 108.09, which implies a leveraged position where debt obligations exceed equity capital. Despite this leverage, the current ratio of 2.49 indicates a robust short-term liquidity position, as the company possesses more than double the current assets required to cover its current liabilities. Finally, the return on equity is -108.7% and the return on assets is -26.6%, metrics that reveal that management has not yet generated positive returns on the capital invested in the business, reflecting the typical negative returns associated with companies that are still in the investment or growth phase of their lifecycle.
Waarderingsbeoordeling
Valuation metrics for Fortress Biotech present a complex picture due to the company's lack of consistent profitability. The trailing twelve-month P/E ratio is listed as N/A because of the negative earnings, while the forward P/E is reported as -1.34, a figure that typically arises when analysts project future earnings that are currently negative or when the denominator involves negative projected earnings, implying uncertainty regarding the trajectory toward profitability. The price-to-book ratio stands at 1.30, indicating that the market is currently valuing the company at 30% above its book value, which suggests a premium placed on the company's intangible assets and future potential despite current losses. Alternative valuation measures provide further context: the price-to-sales ratio is 1.20 and the EV/EBITDA is -1.16, metrics that suggest investors are pricing the stock based on revenue generation and enterprise value multiples rather than earnings power, which is standard practice for biotechnology firms with negative EBITDA. Regarding trading range, the 52-week high is $4.53 and the 52-week low is $1.45; without a specific current share price provided in the facts, the exact percentage distance from these levels cannot be calculated, but the wide range between the high and low demonstrates significant price volatility. Additionally, the beta value is 1.45, which indicates that the stock's price volatility is 45% higher than that of the broader market, signaling that Fortress Biotech is considered a more aggressive investment with higher risk characteristics compared to large-cap, stable market indices.
Growth & Income
The company demonstrates a revenue growth rate of 6.3% year-over-year, while the earnings growth rate is N/A due to the lack of positive earnings data for comparison. In a scenario where earnings are negative, comparing growth rates between revenue and earnings is not mathematically feasible, but the positive revenue growth suggests that the company is successfully expanding its top line even while it struggles to translate that revenue into net profit. As a non-dividend payer, the company does not distribute a dividend yield, which is listed as N/A, nor does it have a payout ratio, which is 0.0%. This 0.0% payout ratio confirms that the company reinvests all available earnings and cash flows back into the business to fund research, development, and commercialization efforts rather than returning capital to shareholders. Consequently, the overall growth and income profile of Fortress Biotech is defined by capital appreciation potential derived from revenue expansion and product development milestones rather than current income generation or dividend distributions, creating a share class designed for investors seeking exposure to high-risk, high-reward biotechnology innovation.